Prokineticin-2 Inhibitors

Prokineticin-2 inhibitors are a class of chemical compounds designed to target and modulate the activity of prokineticin-2 (PK2), a neuropeptide that plays a crucial role in various physiological processes, including circadian rhythms, pain perception, and neuroinflammation. These inhibitors are primarily developed for research purposes and have shown promise in elucidating the intricate mechanisms underlying PK2's functions within the nervous system. PK2, also known as Bv8 or EG-VEGF, exerts its effects through two G protein-coupled receptors, PKR1 and PKR2. Inhibitors of PK2 typically act by disrupting the binding of PK2 to its receptors, thereby blocking downstream signaling pathways.

Structurally, prokineticin-2 inhibitors can take various forms, including small molecules and peptides, which are designed to interact with specific binding sites on PK2 or its receptors. These compounds aim to inhibit PK2-mediated processes, which can be aberrantly activated in certain pathological conditions. The development and characterization of PK2 inhibitors are essential tools for researchers in neuroscience and pharmacology to gain a deeper understanding of the physiological roles of PK2 and its potential implications in various diseases.